Statins for elderly patients with benign prostatic hyperplasia combined metabolic syndrome

Abstract

Objectives To explore clinical application value of statin drugs in elderly patients with benign prostate hyperplasia (BPH) and metabolic syndrome. Methods One hundred cases of elderly patients with benign prostate hyperplasia (BPH) and the metabolic syndrome were admitted in some hospital from May 2010 to May 2012, who were divided into control group (50 cases) and study group (50 canse), and approved by our hospital ethics committee and informed consent of patients to adopt isometric random sampling method. The patients in the control group were treated with other therapy, while the patients in the study group were treated with statins (simvastatin), The clinical therapeutic effects of the two groups were compared after 6 months. Results The patients in study group were treated with statins. The triglycerides, total cholesterol, high–density lipoprotein cholesterol, low density lipoprotein cholesterol, hypersensitive c–reactive protein, interleukin–6, prostate volume and international prostate symptom score were compared with the control group, the difference between the groups was statistically significant (P<0.05); The adverse reaction rate of the study group was 8%, while control group was 20%, and the differences were statistically significant (P<0.05). Conclusions Statins in the treatment of benign prostatic hyperplasia (BPH) and the metabolic syndrome, which can improve the body index by regulating blood lipid, reduce the prostate volume, and stop progression of disease, and no adverse events of statins appear and it is worth popularization because of higher value of clinical application. Key words: Prostatic Hyperplasia; Metabolic Syndrome X; Aged